New Analyst Coverage, from Noble Capital Markets. References ASCO abstracts and gives a 50 cent price target for IUGNF (currently 15 cents).
https://www.imugene.com/analyst-coverage
They suggest preliminary data from the HER-Vaxx Herizon trial was presented as an abstract at ASCO 2022, but i think thats incorrect. Only CF33 and PD1-Vaxx were covered at ASCO 2022 if i'm not mistaken.
GLTAH.
Media Thread, page-5796
-
- There are more pages in this discussion • 10,047 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
-0.001(1.02%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.0¢ | 4.9¢ | $237.3K | 4.848M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 107 | 14460931 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 701942 | 17 |
View Market Depth
| Last trade - 13.08pm 17/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |